Liquid biopsy for profiling of cell free DNA (cfDNA) in blood holds huge promise to transform how we experience and manage cancer by early detection and identification of residual disease and subtype. However, a standard blood draw yields an average of only 10 ng of cfDNA, of which DNA derived from the tumour is a small minority.
DNA comprises molecular information stored in genetic and epigenetic bases, both of which are vital to our understanding of biology. In human genomes, an epigenetic modification at the fifth carbon of cytosines bases comprises one fundamental pathway by which genes can be silenced or activated.
DNA comprises molecular information stored in genetic and epigenetic bases, both of which are vital to our understanding of biology. The interplay between genetics and the DNA epigenome orchestrates complex biological phenomena as diverse as cell fate, ageing, the response to environmental stimuli, and disease pathogenesis.
Explore the fascinating world of the different types of epigenetic modifications and their impacts on gene regulation.
A Q&A with Peter Fromen, CEO of biomodal, emphasising the potential applications of their technology, particularly in oncology, liquid biopsy, aging, and neurodegenerative disorders.
Discover how DNA stores multimodal information through a process known as DNA methylation and its crucial role in gene expression and regulation.
Discover how new technology in next generation sequencing can capture the standard A, C, G, T bases plus epigenetic information in a single workflow.
Uncover the role of DNA methylation in Alzheimer’s disease research, from biomarker discovery to therapeutic potential.
John McShane recently joined biomodal as our Director of Business Development for Eastern North America and Canada.
Chad Geringer recently joined biomodal and focuses on business development in North America.
